• Bateman R. J., Munsell L. Y., Morris J. C., Swarm R., Yarasheski K. E. and Holtzman D. M. (2006) Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856861.
  • Castellano J. M., Kim J., Stewart F. R. et al. (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med., 3, 89ra57.
  • Chang W.-P., Huang X., Downs D., Cirrito J. R., Koelsch G., Holtzman D. M., Ghosh A. K. and Tang J. (2011) β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 25, 775784.
  • Cirrito J. R., May P. C., O'Dell M. A. et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23, 88448853.
  • Comery T. A., Martone R. L., Aschmies S. et al. (2005) Acute γ-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 25, 88988902.
  • De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K. and Van Leuven F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387390.
  • Fukumoto H., Takahashi H., Tarui N. et al. (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimer's disease. J. Neurosci. 30, 1115711166.
  • Garcia Y., Hannam J. C., Harrison T., Hamblett C. L., Hubbs J. L., Kulagowski J. J., Madin A., Ridgill M. P. and Seward E. (2007) Piperidines and related compounds for treatment of Alzheimer's disease. In: WO2007/125364.
  • Hall A., Elliott R. L., Giblin G. M. P., Hussain I., Musgrave J., Naylor A., Sasse R. and Smith B. (2010) Piperidine-derived γ-secretase modulators. Bioorg. Med. Chem. Lett. 20, 13061311.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Hong S., Quintero-Monzon O., Ostaszewski B. L., Podlisny D. R., Cavanaugh W. T., Yang T., Holtzman D. M., Cirrito J. R. and Selkoe D. J. (2011) Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J. Neurosci. 31, 1586115869.
  • Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. and Cole G. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99103.
  • Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H. and Younkin S. G. (2001) Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372381.
  • Kounnas M. Z., Danks A. M., Cheng S. et al. (2010) Modulation of γ-secretase reduces β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67, 769780.
  • Lue L. F., Kuo Y. M., Roher A. E. et al. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853862.
  • Martone R. L., Zhou H., Atchison K. et al. (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer's disease. J. Pharmacol. Exp. Ther. 331, 598608.
  • McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. and Masters C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860866.
  • Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K. and Matsuoka N. (2012) Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32, 20372050.
  • Siemers E., Henley D., Sundell K., Sethuraman G., Dean R., Wrobleski K. and Mohs R. (2011) Evaluating semagacestat, a gamma-secretase inhibitor, in a phase III trial. Alzheimers Dement. 7, S484S485.
  • Van Broeck B., Chen J. M., Tréton G., Desmidt M., Hopf C., Ramsden N., Karran E., Mercken M. and Rowley A. (2011) Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 163, 375389.
  • Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212216.
  • Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Golde T. E. and Koo E. H. (2003) Aβ42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J. Biol. Chem. 278, 3074830754.
  • Wolfe M. S., Xia W., Ostaszewski B. L., Diehl T. S., Kimberly W. T. and Selkoe D. J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398, 513517.